RT Journal Article SR Electronic T1 Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 977 OP 985 DO 10.21873/invivo.12340 VO 35 IS 2 A1 HIROYUKI KODAMA A1 TETSUJI TERAZAWA A1 YASUNOBU ISHIZUKA A1 HIROKI YUKAMI A1 MASAHIKO AOKI A1 TAKAHIRO MIYAMOTO A1 TOSHIFUMI YAMAGUCHI A1 FUTUKARO SHIMAMOTO A1 TAKAYUKI KII A1 MASAHIRO GOTO A1 HIROKI HAMAMOTO A1 WATARU OSUMI A1 MASASHI YAMAMOTO A1 KEITARO TANAKA A1 JYUNJI OKUDA A1 KAZUHISA UCHIYAMA A1 KAZUHIDE HIGUCHI YR 2021 UL http://iv.iiarjournals.org/content/35/2/977.abstract AB Background/Aim: Neoadjuvant chemotherapy without radiation (NAC) shows favorable outcomes for locally advanced rectal cancer (LARC), however, the optimal regimen has not been determined yet. This study aimed to compare the efficacy and safety of oxaliplatin, irinotecan, folinic acid, and 5-fluorouracil (mFOLFOXIRI) with capecitabine/S-1 and oxaliplatin (XELOX/SOX) in rectal cancer patients. Patients and Methods: We retrospectively examined patients with LARC who received mFOLFOXIRI or XELOX/SOX as NAC. Results: Between January 2015 and July 2019, 49 patients received mFOLFOXIRI and 37 patients received XELOX/SOX. The pathological response rates (over two-thirds affected tumor area) were 36.7% and 40.5% in the mFOLFOXIRI and XELOX/SOX groups, respectively. Grade 3/4 neutropenia was experienced by 45.0% of the patients in the mFOLFOXIRI group and 8.0% in the XEOX/SOX group. Conclusion: Although pathological responses were comparable between two groups, mFOLFOXIRI tended to be more toxic compared to XELOX/SOX as NAC for LARC.